Medscape InDiscussion: Lung Cancer

About Medscape InDiscussion: Lung Cancer

Listen to Medscape InDiscussion: Lung Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Publisher

Medscape

Category

health & fitness · science

Language

en

Explicit

No

First episode

11 Aug 2022

Latest episode

9 Jul 2024

Latest episodes

18 episodes in the feed.

1. 

   9 Jul 2024

   S3 Episode 6: NUT Carcinoma: Diagnostic Challenges, Emerging Treatments, and Clinical Trials

   Drs Jacob Sands and Jia Luo discuss NUT carcinoma, including diagnostic challenges, emerging treatments, clinical trial options, and the NUT carcinoma registry. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999032. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics https://pubmed.ncbi.nlm.nih.gov/35372003/ The MYC Oncogene — The Grand Orchestrator of Cancer Growth and Immune Evasion https://pubmed.ncbi.nlm.nih.gov/34508258/ SOX2 Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype https://pubmed.ncbi.nlm.nih.gov/34593608/ Next-Generation Sequencing in Cancer https://pubmed.ncbi.nlm.nih.gov/34408360/ PET Scanning https://www.ncbi.nlm.nih.gov/books/NBK559089/ Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma https://pubmed.ncbi.nlm.nih.gov/38154515/ International NUT Carcinoma Registry https://nc-registry.org/ Automated Tumor Proportion Score Analysis for PD-L1 (22C3) Expression in Lung Squamous Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/34354151/ Ewing Sarcoma https://emedicine.medscape.com/article/990378-overview?form=fpf Improving Lung Cancer Patient Care Through Collaboration, Psychology, and Communication https://www.medscape.com/viewarticle/999028 BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications https://pubmed.ncbi.nlm.nih.gov/37049806/ Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma https://clinicaltrials.gov/study/NCT05019716 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors https://clinicaltrials.gov/study/NCT05372640 Development of CDK4/6 Inhibitors: A Five Years Update https://pubmed.ncbi.nlm.nih.gov/33803309/ A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma https://www.clinicaltrials.gov/search?cond=NCT04718675 Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors https://clinicaltrials.gov/study/NCT05488548

2. 

   11 Jun 2024

   S3 Episode 5: Revolutionizing Small Cell Lung Cancer: A Deep Dive into Immunotherapy Advancements With Dr Hossein Borghaei

   Drs Jacob Sands and Hossein Borghaei discuss small cell lung cancer, including breakthroughs and challenges in immunotherapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999031. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/30280641/ Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/31590988/ Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17167137/ Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort https://pubmed.ncbi.nlm.nih.gov/31629915/ Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/25891174/ Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer (KEYNOTE-001): 3-Year Results From an Open-Label, Phase 1 Study https://pubmed.ncbi.nlm.nih.gov/30876831/ Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/10080612/ Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17135646/ Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://pubmed.ncbi.nlm.nih.gov/32224306/ Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group https://pubmed.ncbi.nlm.nih.gov/21115872/ Beyond Overall Survival: Considering Quality of Life in the Treatment of Early Non-Small Cell Lung Cancer https://www.medscape.com/viewarticle/999479 Tarlatamab for Patients With Previously Treated Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/37861218/

3. 

   9 May 2024

   S3 Episode 4: The Future of Antibody-Drug Conjugates in Lung Cancer Treatment

   Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999030. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress https://pubmed.ncbi.nlm.nih.gov/37163707/ TROP-2 Directed Antibody-Drug Conjugates (ADCs): The Revolution of Smart Drug Delivery in Advanced Non-Small Cell Lung Cancer (NSCLC) https://pubmed.ncbi.nlm.nih.gov/37230055/ Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan https://pubmed.ncbi.nlm.nih.gov/28548889/ Gilead Provides Update on Phase 3 EVOKE-01 Study https://www.gilead.com/news-and-press/press-room/press-releases/2024/1/gilead-provides-update-on-phase-3-evoke-01-study EVOKE-02: A Phase 2 Study of Sacituzumab Govitecan (SG) Plus Pembrolizumab (Pembro) With or Without Platinum Chemotherapy in First-Line Metastatic Non–Small Cell Lung Cancer (NSCLC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS9146 Datopotamab Deruxtecan Met the PFS Endpoint in Previously Treated NSCLC https://dailyreporter.esmo.org/esmo-congress-2023/non-small-cell-lung-cancer/datopotamab-deruxtecan-met-the-pfs-endpoint-in-previously-treated-nsclc Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/ Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial https://pubmed.ncbi.nlm.nih.gov/37694347/ Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/36288547/ Press Release: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint https://www.globenewswire.com/news-release/2023/12/21/2799759/0/en/Press-Release-Sanofi-announces-end-of-program-evaluating-tusamitamab-ravtansine-after-a-2L-NSCLC-Phase-3-trial-did-not-meet-a-primary-endpoint.html Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm? https://pubmed.ncbi.nlm.nih.gov/37370772/ BL-B01D1, a First-in-Class EGFRxHER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients With Locally Advanced or Metastatic Solid Tumor: Results From a First-in-Human Phase 1 Study https://meetings.asco.org/abstracts-presentations/218492

4. 

   11 Apr 2024

   S3 Episode 3: Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

   Drs Jacob Sands and Narjust Florez discuss the nuances of treating women with lung cancer, including screening, treatment, and sexual and reproductive health. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999029). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources The Role of Cultural Humility in Addressing Disparities in Lung Cancer Treatment: How Can Physicians Make a Difference? https://www.medscape.com/viewarticle/969537 Higher Lung Cancer Incidence in Young Women Than Young Men in the United States https://pubmed.ncbi.nlm.nih.gov/29791813/ Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer https://pubmed.ncbi.nlm.nih.gov/37843054/ EGFR Resisters https://egfrcancer.org/ GO2 for Lung Cancer https://go2.org/

5. 

   7 Mar 2024

   S3 Episode 2: Improving Lung Cancer Patient Care Through Collaboration, Psychology, and Communication

   Drs Jacob Sands and Donald L. Rosenstein discuss the psychology of lung cancer and how to effectively communicate with patients about diagnosis, treatment, and expectations. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999028). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2 The Flourishing Scholarship of Psychosocial Oncology Viewed Across 30 Years Through the Lens of This Journal, Psycho-Oncology https://pubmed.ncbi.nlm.nih.gov/35396891/ Living With and Beyond Cancer: Psychosocial and Psychological Support for Patients From Diagnosis Through Survivorship https://www.medscape.com/viewarticle/985096 "Scanxiety" and a Sense of Control: The Perspective of Lung Cancer Survivors and Their Caregivers on Follow-up - A Qualitative Study https://pubmed.ncbi.nlm.nih.gov/37069692/ Psychotherapy Alone Versus Collaborative Psychotherapy and Psychiatric Care in the Treatment of Depression and Anxiety in Patients With Cancer: A Naturalistic, Observational Study https://pubmed.ncbi.nlm.nih.gov/37209423/ Creating a Proactive Interdisciplinary Approach to Care: Embedding Oncology Care Coordination Within an Oncology Patient and Family Support Program https://ascopubs.org/doi/10.1200/JCO.2022.40.28_suppl.051 Use of PHQ-9 for Monitoring Patients With Depression in Integrated Primary Care Practices https://pubmed.ncbi.nlm.nih.gov/36693193/ Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a Primary Care Setting https://pubmed.ncbi.nlm.nih.gov/32582485/ Implementing Collaborative Care for Major Depression in a Cancer Center: An Observational Study Using Mixed-Methods https://pubmed.ncbi.nlm.nih.gov/35305403/

6. 

   7 Mar 2024

   S3 Episode 1: What Are the Latest Improvements in Targeted Therapy Options and Diagnostic Technology for Lung Cancer Patients?

   Drs Jacob Sands and Julia Rotow discuss the latest breakthroughs in lung cancer treatment, including targeted therapy options, toxicities, and diagnostic technology. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999027). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening https://www.medscape.com/viewarticle/984258 EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/ Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29151359/ Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2). 2023 World Conference on Lung Cancer. Abstract PL03.13. https://www.sciencedirect.com/science/article/abs/pii/S1556086423008110 MARIPOSA: Phase 3 Study of First-Line Amivantamab + Lazertinib Versus Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34911336/ Discovery of Amivantamab (JNJ-61186372), a Bispecific Antibody Targeting EGFR and MET https://pubmed.ncbi.nlm.nih.gov/33839159/ Amivantamab Plus Chemotherapy With and Without Lazertinib in EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib: Primary Results From the Phase III MARIPOSA-2 Study https://pubmed.ncbi.nlm.nih.gov/37879444/ Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/33380864/ Next Generation Sequencing Technology in Lung Cancer Diagnosis https://pubmed.ncbi.nlm.nih.gov/34571741/ Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/ Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress https://pubmed.ncbi.nlm.nih.gov/33558193/ [NCT03456076] A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03456076 Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies https://pubmed.ncbi.nlm.nih.gov/33172113/ Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2302299 NCCN Guidelines: Non-Small Cell Lung Cancer https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 Amivantamab Plus Chemotherapy in NSCLC With EGFR Exon 20 Insertions https://pubmed.ncbi.nlm.nih.gov/37870976/

7. 

   15 Jun 2023

   S2 Episode 6: How Can Clinicians Recognize and Address Stigma and Bias to Improve Treatment Disparities in Lung Cancer?

   Drs Jacob Sands and Christopher Lathan, MD, discuss stigma, clinician bias, financial toxicity, and treatment disparities in lung cancer, including helpful practices such as "following the no." Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984264). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2 Racial and Ethnic Disparities https://www.lung.org/research/state-of-lung-cancer/racial-and-ethnic-disparities Stage IIIB Non–Small Cell Lung Cancer https://www.cancer.gov/publications/dictionaries/cancer-terms/def/stage-iiib-non-small-cell-lung-cancer Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names https://pubmed.ncbi.nlm.nih.gov/28550031/ Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/26926678/ How Structural Racism Works – Racist Policies as a Root Cause of US Racial Health Inequities https://pubmed.ncbi.nlm.nih.gov/33326717/

8. 

   17 May 2023

   S2 Episode 5: Immunotherapy, Next-Generation Sequencing, and Shared Decision-Making in the Treatment of Non–Small Cell Lung Cancer

   Drs Jacob Sands and Stephen V. Liu discuss immunotherapy, biomarkers, next-generation sequencing, shared decision-making, and improving outcomes in the treatment of non–small cell lung cancer. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984262). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30955977/ Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer Without Tumor PD-L1 Expression: A Pooled Analysis of 3 Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/32914866/ Patient-Reported Outcomes Following Pembrolizumab or Placebo Plus Pemetrexed and Platinum in Patients With Previously Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/32035514/ Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/30280635/ Nanoparticle Albumin-Bound Paclitaxel: A Novel Cremphor-EL®-Free Formulation of Paclitaxel https://www.medscape.com/viewarticle/563323_4 Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29658856/ First-line Treatment With Ipilimumab Plus Nivolumab for NSCLC https://decisionpoint.medscape.com/oncology/viewarticle/925934 Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/31562796/ First-line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33476593/ Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study https://pubmed.ncbi.nlm.nih.gov/36327426/ The importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912095/ STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/29773717/ Atezolizumab for First-line Treatment of PD-L1-Selected Patients With NSCLC https://pubmed.ncbi.nlm.nih.gov/32997907/ Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared With Chemotherapy Alone as First-line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/31122901/ Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/17167137/ Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor (TKI)-Resistant Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) https://clinicaltrials.gov/ct2/show/NCT03515837 Dual Inhibition of EGFR‑VEGF: An Effective Approach to the Treatment of Advanced Non‑Small Cell Lung Cancer With EGFR Mutation (Review) https://pubmed.ncbi.nlm.nih.gov/36601768/ EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/

9. 

   18 Apr 2023

   S2 Episode 4: Lung Cancer Screening: Where Guidelines and Clinical Judgment Intersect in the Evaluation of Suspicious Nodules

   Drs Jacob Sands and Chi-Fu J. Yang discuss lung cancer screening trials and the intersection of guidelines and clinical judgment in evaluation of suspicious nodules. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984261). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Rescue Lung Society https://rescuelung.org/ Lung Cancer https://www.medscape.com/resource/lungcancer/rc-lungcancer2 American Lung Cancer Screening Initiative https://www.alcsi.org/ Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview Lung Cancer: Screening https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening Reduced Lung-cancer Mortality With Low-dose Computed Tomographic Screening https://pubmed.ncbi.nlm.nih.gov/21714641/ Reduced Lung-cancer Mortality With Volume CT Screening in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/31995683/ Low-dose CT Scan https://www.cancer.gov/publications/dictionaries/cancer-terms/def/low-dose-ct-scan NELSON Study Shows CT Screening for Nodule Volume Management Reduces Lung Cancer Mortality by 26 Percent in Men https://www.iaslc.org/iaslc-news/press-release/nelson-study Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial: New Confirmation of Lung Cancer Screening Efficacy https://pubmed.ncbi.nlm.nih.gov/30937431/ Statistical Essentials in Interpreting Clinical Trials https://www.medscape.com/viewarticle/863840 American Lung Association State of Lung Cancer https://www.lung.org/research/state-of-lung-cancer Lung CT Screening Reporting & Data System (Lung-RADS®) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads Surgical Outcomes in a Large, Clinical, Low-dose Computed Tomographic Lung Cancer Screening Program https://pubmed.ncbi.nlm.nih.gov/26209493/ Navigational Bronchoscopy: A Guide Through History, Current Use, and Developing Technology https://pubmed.ncbi.nlm.nih.gov/32642249/ PET Scan https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pet-scan Lung Screening Benefits and Challenges: A Review of the Data and Outline for Implementation https://pubmed.ncbi.nlm.nih.gov/33188913/

10. 

    16 Mar 2023

    S2 Episode 3: Standard of Care in Perioperative Management of Lung Cancer: The Past, Present, and Future

    Drs Jacob Sands and Jamie Chaft discuss the past, present, and future of perioperative management of lung cancer, including data from recent trials, disease-free survival outcomes, and changes in the standard of care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/14736927/ Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (IMpower010): A Randomized, Multicentre, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/34555333/ Integration of Immunotherapy Into Adjuvant Therapy for Resected Non–Small-Cell Lung Cancer: ALCHEMIST Chemo-IO (ACCIO) https://pubmed.ncbi.nlm.nih.gov/33878954/ Pembrolizumab Versus Placebo as Adjuvant Therapy for Completely Resected Stage IB-IIIA Non–Small-Cell Lung Cancer (PEARLS/KEYNOTE-091): An Interim Analysis of a Randomized, Triple-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/36108662/ ADAURA: Phase III, Double-Blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-Stage NSCLC After Complete Surgical Resection https://pubmed.ncbi.nlm.nih.gov/29789220/ Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/ Osimertinib as Adjuvant Therapy in Patients (pts) With Stage IB–IIIA EGFR Mutation Positive (EGFRm) NSCLC After Complete Tumor Resection: ADAURA. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA5 American Joint Committee on Cancer https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/ Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/28885881/ Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non–Small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) https://www.clinicaltrials.gov/ct2/show/NCT02595944 ALINA: A Phase III Study of Alectinib Versus Chemotherapy as Adjuvant Therapy in Patients With Stage IB–IIIA Anaplastic Lymphoma Kinase-Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC). https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.TPS8569 Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://pubmed.ncbi.nlm.nih.gov/35403841/

11. 

    16 Feb 2023

    S2 Episode 2: Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening

    Drs Jacob Sands and Julia Rotow discuss genomic testing, treatment options, and clinical trials for young adults who do not qualify for lung cancer screening. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Lung Cancer https://www.medscape.com/resource/lungcancer Lung Cancer in Patients Under the Age of 40 Years https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687453/ Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States https://jamanetwork.com/journals/jamaoncology/article-abstract/2773380 What Are the Risks and Benefits of Lung Cancer Screening? https://www.medscape.com/viewarticle/969532 Biomarker Tissue Journey Among Patients With Untreated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network https://pubmed.ncbi.nlm.nih.gov/35313244/ Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States https://pubmed.ncbi.nlm.nih.gov/35737912/ Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer https://jamanetwork.com/journals/jamaoncology/fullarticle/2475482 Biology of Young Lung Cancer Study: The YOUNG LUNG Study https://clinicaltrials.gov/ct2/show/NCT05265429 Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) https://www.clinical-lung-cancer.com/article/S1525-7304(22)00265-0/fulltext Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations https://linkinghub.elsevier.com/retrieve/pii/S1525-1578(22)00080-0 Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482929/ Immune Checkpoint Inhibitors for Patients With Advanced Lung Cancer and Oncogenic Driver Alterations: Results From the IMMUNOTARGET Registry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389252/ Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419340/ Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(22)01068-6 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Induced Hepatic Failure in Lung Cancer Patients: A Study of Signal Mining and Analysis of the FDA Adverse Event Reporting System Database https://pubmed.ncbi.nlm.nih.gov/33768534/ A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) https://www.clinicaltrials.gov/ct2/show/NCT03157128

12. 

    16 Feb 2023

    S2 Episode 1: Are We Ready to Use the Word "Cure" When Talking About Small Cell Lung Cancer Treatment?

    Drs Jacob Sands and Jared Weiss discuss subtypes; ongoing clinical trials; durable, ongoing responses to therapy; and the potential for using the word "cure" in the treatment of small cell lung cancer. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Immunotherapy and Lung Cancer Treatment https://www.medscape.com/viewarticle/969534 Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://ascopubs.org/doi/10.1200/JCO.2006.06.5821 Study of Trilaciclib and Lurbinectidin https://clinicaltrials.gov/ct2/show/NCT05578326 PL02.03 Lurbinectedin/Doxorubicin Versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial https://www.jto.org/article/S1556-0864(21)02453-9/fulltext Erythropoiesis-Stimulating Agents in Oncology: A Study-Level Meta-Analysis of Survival and Other Safety Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816662 First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) https://clinicaltrials.gov/ct2/show/NCT05361395 Bispecific T-Cell Engager (BiTE) Antibodies https://reference.medscape.com/drugs/bispecific-t-cell-engager-bite-antibodies

13. 

    13 Dec 2022

    S1 Episode 6: The Role of Cultural Humility in Addressing Disparities in Lung Cancer Treatment: How Can Physicians Make a Difference?

    Drs Jacob Sands and Narjust Florez discuss the importance of cultural humility in addressing bias and disparities in lung cancer, including screenings, patient care, hospice, and access to treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969537). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals. Resources Assessing the Documentation of Social Determinants of Health for Lung Cancer Patients in Clinical Narratives https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35419333/ Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening Race and Sex Differences in Patient Provider Communication and Awareness of Lung Cancer Screening in the Health Information National Trends Survey, 2013–2017 https://pubmed.ncbi.nlm.nih.gov/31054908/ Racial and Ethnic Disparities Among State Medicaid Programs for Breast Cancer Screening https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840870 The Tuskegee Timeline https://www.cdc.gov/tuskegee/timeline.htm Are Racial and Ethnic Minorities Less Willing to Participate in Health Research? https://pubmed.ncbi.nlm.nih.gov/16318411/ Abstract 1641: Utilization of Palliative Therapies Among Hispanics With Stage IV Non-Small Cell Lung Cancer https://aacrjournals.org/cancerres/article/78/13_Supplement/1641/625802/Abstract-1641-Utilization-of-palliative-therapies Early Palliative Care for Patients With Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1000678 Medicaid Patients More Likely to Die at Home Without Hospice During the Pandemic Versus Before, Exacerbating Disparities With Commercially Insured Patients https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.6502 Assessment of Parking Fees at National Cancer Institute–Designated Cancer Treatment Centers https://jamanetwork.com/journals/jamaoncology/article-abstract/2768017 Cultural Humility: Essential Foundation for Clinical Researchers https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834043/

14. 

    15 Nov 2022

    S1 Episode 5: Small Cell Lung Cancer: What Are the First-line and Second-line Treatment Options?

    Drs Jacob Sands and Lauren Byers discuss the treatment options for patients diagnosed with small cell lung cancer and the future possibility of durable responses. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969536). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals. Resources FDA Approval Summary: Atezolizumab and Durvalumab in Combination With Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100557 First-line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-term Follow-up Results https://www.iaslc.org/iaslc-news/press-release/first-line-pembrolizumab-or-placebo-combined-etoposide-and-platinum-es Lurbinectedin Prescribing Information https://pp.jazzpharma.com/pi/zepzelca.en.USPI.pdf Lurbinectedin as Second-line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-label, Phase 2 Basket Trial https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(20)30068-1 Trilaciclib Prescribing Information https://www.g1therapeutics.com/file.cfm/69/docs/NDA_214200_COSELA_PI_20210212_US-2100006.pdf Primary Analysis From the Phase 2 Study of Continuous Talazoparib (TALA) Plus Intermittent Low-Dose Temozolomide (TMZ) in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.8517?af=R Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319046/ Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker https://clinicaltrials.gov/ct2/show/NCT04334941 The Role of Schlafen 11 (SLFN11) as a Predictive Biomarker for Targeting the DNA Damage Response https://www.nature.com/articles/s41416-020-01202-y Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538259/ Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC With Distinct Therapeutic Vulnerabilities https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30662-0 Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward https://www.nature.com/articles/nrc.2017.87 First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064 Durvalumab Plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext

15. 

    13 Oct 2022

    S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy

    Drs Jacob Sands and Benjamin Levy discuss the management of lung cancer with neoadjuvant and adjuvant therapy and the potential impact of current clinical trials. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969535). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group https://ascopubs.org/doi/pdf/10.1200/JCO.2007.13.9030 ADAURA: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2027071 Osimertinib: Medscape Drugs & Diseases https://reference.medscape.com/drug/tagrisso-osimertinib-1000062 Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext Atezolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/tecentriq-atezolizumab-1000098 Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext Pembrolizumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/keytruda-pembrolizumab-999962 Pembrolizumab (Pembro) Versus Placebo for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Following Complete Resection and Adjuvant Chemotherapy (Chemo) When Indicated: Randomized, Triple-Blind, Phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Study https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/pearls-keynote-091-pembrolizumab-pembro-versus-placebo-for-early-stage-non-small-cell-lung-cancer-nsclc-following-complete-resection-and-adjuvant-chemotherapy Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2202170 Nivolumab: Medscape Drugs & Diseases https://reference.medscape.com/drug/opdualag-nivolumab-relatlimab-4000249 Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) https://ascopubs.org/doi/full/10.1200/JCO.21.02660 New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) https://clinicaltrials.gov/ct2/show/NCT04564157 Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer https://www.lungcancerresearchfoundation.org/research/lung-cancer-mutation-consortium/current-lcmc-study/ ALCHEMIST: Adjuvant Targeted Therapy or Immunotherapy for High-Risk Resected NSCLC https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.TPS9077 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study https://www.clinicaltrials.gov/ct2/show/NCT04267848

16. 

    15 Sept 2022

    S1 Episode 3: Immunotherapy and Lung Cancer Treatment

    Drs Jacob Sands and Jared Weiss discuss immunotherapy, including the importance of genomic testing, recent studies, new regimens, and the future of lung cancer treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969534). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals. Resources Severe Immune-Related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib https://www.annalsofoncology.org/article/S0923-7534(19)31165-2/fulltext Pembrolizumab Versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1606774 Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of At Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-67362100228-2/fulltext Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression https://ascopost.com/issues/may-10-2021/cemiplimab-rwlc-for-first-line-treatment-of-nsclc-with-high-pd-l1-expression/ Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1801005 Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1810865 Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC https://www.nejm.org/doi/10.1056/NEJMoa1716948 IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC https://www.jto.org/article/S1556-0864(21)02322-4/fulltext First-Line Nivolumab plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1910231 FDA Approves Nivolumab plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression ≥1%) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1 Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors (ICI) in Advanced Non-Small Cell Lung Cancer (aNSCLC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9048?af=R First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064 Durvalumab plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301) https://clinicaltrials.gov/ct2/show/NCT05060016

17. 

    11 Aug 2022

    S1 Episode 2: Biomarkers and Targeted Therapies for Lung Cancer

    Drs Jacob Sands and Pasi Jänne discuss the effectiveness of biomarkers and targeted therapies for lung cancer. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969533). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals. Resources Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma https://www.nejm.org/doi/full/10.1056/nejmoa0810699 The Value of Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer https://www.medscape.org/viewarticle/975903 ctDNA Shows Promise for Assessing Lung Cancer Treatment Response https://www.medscape.com/viewarticle/965587 Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2005653 Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC https://www.nature.com/articles/s41586-021-03898-1 Targeting Uncommon EGFR Mutations in Advanced NSCLC https://reference.medscape.com/recap/952720 Afatinib Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf Amivantamab Prescribing Information https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf Mobocertinib Prescribing Information https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1 Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa1713137 Real-World Incidence and Impact of Pneumonitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: a Multi-institutional Cohort Study https://jitc.bmj.com/content/10/6/e004670.long

18. 

    11 Aug 2022

    S1 Episode 1: What Are the Risks and Benefits of Lung Cancer Screening?

    Drs Jacob Sands and Shawn Regis discuss the risks and benefits of lung cancer screening. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969532). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources National Lung Screening Trial https://www.cancer.gov/types/lung/research/nlst Lung Cancer: Screening, 1996 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-1996 NELSON Lung Cancer Screening Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266562/ Early Lung Cancer Detection in High Risk Individuals (MILD) https://clinicaltrials.gov/ct2/show/NCT02837809 Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force https://www.ncbi.nlm.nih.gov/books/NBK568573/ Appendix A Table 5. Recommendations for Lung Cancer Screening With LDCT https://www.ncbi.nlm.nih.gov/books/NBK568579/table/appa.tab5/?report=objectonly ALA Press Release https://www.lung.org/media/press-releases/new-sbts-psa-1 Lung CT Screening Reporting & Data System (Lung-RADS) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads Outcomes of Positive and Suspicious Findings in Clinical CT Lung Cancer Screening and the Road Ahead https://pubmed.ncbi.nlm.nih.gov/34818144/ Lung Cancer Incidence and Mortality With Extended Follow-up in the National Lung Screening Trial https://www.jto.org/article/S1556-0864(19)30473-3/fulltext Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation https://www.jto.org/article/S1556-0864(20)30993-X/fulltext American Thoracic Society and American Lung Association Implementation Guide for Lung Cancer Screening https://www.lungcancerscreeningguide.org/ Rescue Lung Society https://rescuelung.org/ Lung Cancer Screening Resources https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan/resources Go2 Foundation for Lung Cancer https://go2foundation.org/

Contact Medscape InDiscussion: Lung Cancer

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.